SFE Investment Counsel lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,727 shares of the company’s stock after selling 519 shares during the period. Johnson & Johnson comprises about 1.4% of SFE Investment Counsel’s holdings, making the stock its 22nd largest position. SFE Investment Counsel’s holdings in Johnson & Johnson were worth $2,784,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Goodman Financial Corp acquired a new position in Johnson & Johnson in the 4th quarter valued at about $104,000. Stelac Advisory Services LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at about $108,000. Price Wealth Management Inc. acquired a new position in Johnson & Johnson in the 4th quarter valued at about $148,000. Roble Belko & Company Inc increased its position in Johnson & Johnson by 59.7% in the 4th quarter. Roble Belko & Company Inc now owns 1,164 shares of the company’s stock valued at $163,000 after acquiring an additional 435 shares during the period. Finally, Cerebellum GP LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at about $166,000. Institutional investors and hedge funds own 65.96% of the company’s stock.
Several equities analysts recently issued reports on the company. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b” rating in a research report on Friday, May 18th. ValuEngine cut Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Tuesday, May 22nd. Credit Suisse Group set a $151.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, June 12th. Deutsche Bank reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, April 18th. Finally, Jefferies Financial Group set a $153.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a report on Friday, April 13th. Six equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $142.23.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.06. The business had revenue of $20.01 billion for the quarter, compared to analyst estimates of $19.50 billion. Johnson & Johnson had a return on equity of 30.65% and a net margin of 1.58%. The company’s quarterly revenue was up 12.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.83 EPS. analysts expect that Johnson & Johnson will post 8.13 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, June 12th. Stockholders of record on Tuesday, May 29th were paid a dividend of $0.90 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend was Friday, May 25th. This represents a $3.60 annualized dividend and a dividend yield of 2.93%. Johnson & Johnson’s payout ratio is 49.32%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.